Roivant Sciences (NASDAQ:ROIV) CEO Sells $7,022,000.00 in Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) CEO Eric Venker sold 200,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 20th. The stock was sold at an average price of $35.11, for a total value of $7,022,000.00. Following the sale, the chief executive officer owned 1,399,154 shares of the company’s stock, valued at approximately $49,124,296.94. The trade was a 12.51% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Eric Venker also recently made the following trade(s):

• On Wednesday, September 30th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The shares were sold at an average price of $36.62, for a total value of $7,324,000.00.
• On Friday, August 28th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The shares were sold at an average price of $35.77, for a total transaction of $7,154,000.00.
• On Monday, July 27th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The stock was sold at an average price of $34.95, for a total value of $6,990,000.00.

Roivant Sciences Stock Up 1.8%

ROIV traded up $0.65 during trading on Thursday, hitting $37.45. 13,451,164 shares of the stock were exchanged, compared to its average volume of 6,449,771. The stock has a fifty day moving average price of $36.59 and a two-hundred day moving average price of $33.26. The firm has a market capitalization of $27.05 billion, a P/E ratio of -70.66 and a beta of 1.10. Roivant Sciences Ltd. has a 1-year low of $17.89 and a 1-year high of $42.50.

Roivant Sciences (NASDAQ:ROIV) last issued its quarterly earnings results on Friday, August 7th. The company reported ($0.26) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.04. Roivant Sciences had a negative net margin of 3,534.96% and a negative return on equity of 22.94%. The firm had revenue of $1.44 million during the quarter, compared to analysts’ expectations of $2.06 million. Analysts predict that Roivant Sciences Ltd. will post -2.00 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on ROIV shares. Citigroup reiterated a “buy” rating on shares of Roivant Sciences in a research report on Monday, October 12th. Wolfe Research cut Roivant Sciences from an “outperform” rating to a “peer perform” rating in a report on Monday, October 12th. Stifel Nicolaus initiated coverage on shares of Roivant Sciences in a report on Wednesday, September 16th. They issued a “buy” rating and a $51.00 price target on the stock. Sanford C. Bernstein raised Roivant Sciences to a “strong-buy” rating in a research note on Wednesday, July 29th. Finally, HC Wainwright boosted their price target on Roivant Sciences from $41.00 to $47.00 and gave the company a “buy” rating in a report on Tuesday, September 8th. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Roivant Sciences has a consensus rating of “Moderate Buy” and an average price target of $45.64.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of ROIV. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in Roivant Sciences during the 2nd quarter worth $2,166,000. Squarepoint Ops LLC acquired a new position in Roivant Sciences during the 2nd quarter worth $16,830,000. Arizona State Retirement System increased its holdings in Roivant Sciences by 24.4% in the second quarter. Arizona State Retirement System now owns 128,364 shares of the company’s stock valued at $4,543,000 after buying an additional 25,199 shares during the last quarter. Allspring Global Investments Holdings LLC bought a new stake in shares of Roivant Sciences in the 1st quarter valued at approximately $3,957,000. Finally, Bank of America Corp DE raised its holdings in shares of Roivant Sciences by 8.0% during the first quarter. Bank of America Corp DE now owns 3,163,821 shares of the company’s stock worth $87,638,000 after purchasing an additional 235,493 shares during the period. 64.76% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Roivant Sciences

Here are the key news stories impacting Roivant Sciences this week:

• Positive Sentiment: Successful Phase 3 trials: Brepocitinib met the primary endpoint in both the CLARITY-1 and CLARITY-2 studies. It also delivered statistically significant and clinically meaningful improvements across key secondary measures, including sustained steroid-free disease control at Week 48, reduced chorioretinal vascular leakage, resolution of macular edema and improved patient-reported visual functioning. Roivant and Priovant Announce Positive Results in CLARITY-1 and CLARITY-2 Phase 3 Trials
• Positive Sentiment: Commercial opportunity expanded: The trial outcomes may enable Roivant and Priovant to seek a label expansion for Lisraya in uveitis, potentially broadening the product’s addressable market. The benefits were reported despite an aggressive steroid taper, which may make the data more compelling for physicians seeking to reduce steroid exposure. Roivant to Seek Label Expansion for Lisraya in Uveitis
• Positive Sentiment: Investor reaction: Multiple market reports characterized the stock’s move as a response to the positive uveitis data, indicating that investors viewed the results as an important clinical and pipeline catalyst. Roivant Sciences Says Brepocitinib Meets Primary Goal in Uveitis Trials
• Neutral Sentiment: Upcoming financial update: Roivant will report results for the quarter ended September 30, 2026, and provide a business update on November 9. The call could offer additional information on regulatory plans, commercialization timing and the broader pipeline. Roivant to Report Second-Quarter Financial Results

Roivant Sciences Company Profile

Roivant Sciences Ltd. (NASDAQ: ROIV) is a biopharmaceutical company focused on discovering, developing and commercializing medicines. The company organizes its activities through subsidiaries and partner companies, often referred to as “Vants,” which specialize in particular therapeutic areas and stages of drug development.

Roivant’s research and development activities have included immunology, dermatology, women’s health, rare diseases and other specialty-care fields. Its portfolio has included Vtama (tapinarof) cream, a nonsteroidal topical treatment approved in the United States for plaque psoriasis and atopic dermatitis.